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In Brief
Vijayraghavan et al. report that muscarinic M1 receptor blockade did not reproduce the effects of general muscarinic antagonism on maintenance of behavioral rules in prefrontal cortical neurons. M1 receptor stimulation consistently inhibited prefrontal neurons and overstimulation disrupted maintenance of rules.
INTRODUCTION
Corticopetal innervation of the prefrontal cortex (PFC) by the basal forebrain cholinergic system has a critical modulatory role in cognition and controlled behavior (Croxson et al., 2011; Mesulam, 2013) . Acetylcholine (ACh), through synaptic specializations and volume transmission (Mrzljak et al., 1995) , acts on pre-and postsynaptic cholinergic receptors to influence cortical function in a variety of contexts, including working memory (WM; Croxson et al., 2011; Zhou et al., 2011) and attentional gating of visual stimuli (Herrero et al., 2008; Parikh et al., 2007) . ACh exerts its influence through ionotropic nicotinic (Picciotto et al., 2012) and metabotropic muscarinic receptors (Thiele, 2013) . The dorsolateral PFC (DLPFC) is a crucial node in a network of areas involved in higher-order cognitive functions, including WM (Fuster and Alexander, 1971) , attentional processing (Miller and Cohen, 2001) , maintenance of abstract rules to guide responses (Everling and DeSouza, 2005; Wallis et al., 2001) , and inhibition of inappropriate responses (Condy et al., 2007) . Dysfunction of the PFC accompanies many disorders of cognition (Arnsten et al., 2012) , and cholinergic system pathology is widely implicated in the etiology of psychiatric disorders with cognitive pathology, including Alzheimer's disease (Mesulam, 2013) and schizophrenia (Carruthers et al., 2015) .
While behavioral studies have established that muscarinic receptor blockade is detrimental to cognition (Klinkenberg and Blokland, 2010) , and to specific PFC executive functions (Chudasama et al., 2004; Zhou et al., 2011) , the downstream mechanisms by which muscarinic actions regulate PFC function and receptor subtype contributions thereof remain poorly understood. Both cholinergic deafferentation of PFC (Croxson et al., 2011) and systemic injections of the general muscarinic antagonist scopolamine (Zhou et al., 2011) cause spatial WM performance deficits in monkeys. We have previously reported that iontophoretic application of scopolamine on monkey DLPFC neurons suppresses DLPFC neuronal activity and diminishes rule representation, stimulus, and saccade direction selectivity in neuronal responses in a task in which rules maintained in WM specify oculomotor responses (Major et al., 2015) . However, the muscarinic receptor subtypes involved in this suppression of PFC neuronal activity and task representation in primates remain enigmatic.
There are five muscarinic receptor subtypes, comprised of the G q -coupled M1, M3, and M5 receptors and G i/o -coupled M2 and M4 receptors . M1 receptors (M1Rs) are the most prominently expressed subtype in primate PFC, found in postsynaptic specializations on dendritic spines of pyramidal neurons (Mrzljak et al., 1993) , and have an excitatory influence on cortical physiology in brain slices (Carr and Surmeier, 2007) . M2 receptors (M2Rs) are also expressed in PFC, both as a presynaptic autoreceptor on cholinergic axons and as a postsynaptic heteroreceptor on glutamatergic and GABAergic synapses, and are posited to have an inhibitory influence on neuronal activity (Medalla and Barbas, 2012) . Since the ACh binding site on muscarinic receptor subtypes is homologous and highly conserved, orthosteric agonists targeting this site do not possess high subtype selectivity .
The recent synthesis of muscarinic compounds possessing high subtype selectivity, by acting on allosteric sites on muscarinic receptors, enables analysis of the contributions of individual receptor subtypes in PFC cognitive physiology during normal behavior and in models of cognitive disorders Conn et al., 2009; Digby et al., 2012) .
Muscarinic stimulation improves cognitive indicators in patients with Alzheimer's disease (Bodick et al., 1997) and schizophrenia (Shekhar et al., 2008) . M1R activators improve cognitive performance during self-ordered spatial search in monkeys (Uslaner et al., 2013) and augment medial PFC activity in rodents (Shirey et al., 2009 ). M1R stimulation facilitates hippocampal long-term potentiation (LTP) (Buchanan et al., 2010) , and is expected to engender cognitive enhancement due to increased excitability of PFC cortical neurons by blockade of potassium currents, including the M-current (Wang et al., 2011) .
Here, we examined the effects of local M1R stimulation and blockade on PFC neuronal physiology in rhesus monkeys while they performed a task in which a rule, maintained in WM, directed the execution of a prosaccade toward a peripheral stimulus, or inhibition of that reflexive response, and execution of a saccade away from the stimulus (antisaccade; Hallett, 1978) . This task, incorporating many PFC-dependent functions, including maintenance of task set, automatic-response inhibition, and motor reprogramming, is sensitive to PFC integrity in humans (Guitton et al., 1985; Rivaud et al., 1994) and monkeys (Condy et al., 2007; Koval et al., 2011) . Impairment of antisaccade execution is a clinical manifestation of Alzheimer's disease (Fletcher and Sharpe, 1986) and schizophrenia (Fukushima et al., 1988) . Based on previous results with general muscarinic blockade (Major et al., 2015; Zhou et al., 2011) and other studies summarized above, we hypothesized that M1R blockade would suppress excitability and disrupt task selectivity of PFC neurons, while M1R stimulation would enhance rule representation by increasing PFC excitability.
Unexpectedly, we found that M1R stimulation predominantly and dose-dependently inhibited PFC neurons, with disruption of trial rule representation at higher doses. Moreover, M1R blockade also suppressed PFC excitability, but had no consistent effects on trial rule representation, in contrast with the strong suppression of rule representation in WM observed upon general muscarinic blockade (Major et al., 2015) . Our results suggest that M1R overstimulation may be detrimental to PFC activity in behaving subjects with endogenous cholinergic tone, and that other muscarinic receptor subtypes mediate the disruptive effects of muscarinic blockade on cognitive representations in PFC neuronal activity.
RESULTS
We pharmacologically tested 152 neurons from the DLPFC of two rhesus macaques (monkey O, 58; monkey T, 94; Figures 1A and 1B) performing the rule working memory antisaccade task ( Figure 1C ). We tested 56 neurons with iontophoretic application of M1R allosteric agonist, VU0357017; 17 neurons with saline followed by VU0357017; 24 neurons with M1R-preferring agonist, McN-A-343; and 55 neurons with M1R-preferring antagonist, pirenzepine. After excluding neurons whose average activity throughout the session was less than 1 Hz (STAR Methods), we analyzed the effects of VU0357017 (n = 47), McN-A-343 (n = 18), and pirenzepine (n = 47) on general neuronal physiology and task selectivity. Behavioral trial count statistics for the population are shown in Table S1 .
Effects of M1R Agents on DLPFC Neuronal Physiology
Based on our previously published findings and other studies with muscarinic antagonist scopolamine (Major et al., 2015; Zhou et al., 2011) , we hypothesized that M1R stimulation with VU0357017 would increase DLPFC neuronal excitability, while M1R blockade with pirenzepine would suppress activity. We found that VU0357017 application suppressed average trial activity of DLPFC neurons ( Figure 2A , top panel; n = 47; p = 0.005, Wilcoxon sign-rank test, control versus drug activity). A majority of neurons (62%; p < 0.05, Wilcoxon rank-sum test on each neuron) were significantly inhibited by M1R stimulation (Figure 2A, bottom panel) . We then examined the dose dependence of effects of VU0357017 on neuronal activity to ascertain if neuronal suppression was monotonic with drug dose. We found that M1R stimulation at lower doses (%20 nA) had no significant effects on population activity (Figure 2B , left; n = 35), while higher ejection doses (21-100 nA) induced significant neuronal activity suppression (Figure 2B , right; n = 26, p = 0.001). At lower doses, 49% of neurons tested were significantly inhibited, while 31% were excited ( Figure 2B , left pie chart). Higher dose application significantly inhibited most DLPFC neurons (81%) while only 4 neurons were excited ( Figure 2B , right pie chart). The proportion of DLPFC neurons inhibited by drug application was significantly different between the dose ranges (low versus high doses; p = 0.016, Fisher exact test). In 23 neurons ( Figure 2C ), we found that mean activity showed significant recovery after druginduced suppression (p control-drug = 0.006; p drug-recovery = 0.019) with two-thirds of significantly inhibited neurons exhibiting successful recovery (Table S1 ).
Microiontophoresis involves passage of very small currents (0-100 nA range) to electrically repulse charged molecules with the same polarity into the neuronal milieu. Previous studies have demonstrated that current application itself does not affect neuronal physiology (Vijayraghavan et al., 2007) . To further confirm this, we tested Na + (saline) application in 17 DLPFC neurons, which did not result in inhibition (p control-Na + = 0.99, one-tailed sign-rank test), while subsequent comparable application of VU0357017 at positive ejection current polarities inhibited those neurons (p Na + -drug = 0.001).
Further, in 12 neurons tested with saline, M1R agonist, and recovery, neuronal activity recovered after M1R agonist application (p drug-recovery = 0.003, sign-rank test with Holm-Bonferroni correction). Thus, activity suppression due to M1R stimulation by VU0357017 was not an artifact of iontophoretic currents. To further confirm that neuronal suppression was not an artifact of the drug ejection protocol or technique, we also stimulated M1R by pulsed pneumatic pressure ejection of VU0357017 onto neurons. This allowed us to rapidly apply small amounts of drugs with a pulse schedule and mitigated potential consequences of prolonged current-induced ejection. Pressure ejection of VU0357017 reliably resulted in suppression of the activity of PFC neurons (Figures S1A and S1B) , while comparable ejection of saline had no effect ( Figure S1A ). Thus, neuronal inhibition by the M1R allosteric agonist was not a consequence of the drug application methodology and was also reproduced when the drug was intermittently applied with pneumatic ejection. Moreover, to preclude the possibility that neuronal suppression observed after M1R blockade was an idiosyncrasy of the pharmacology of the M1R-selective agent used (VU0357017), we also tested DLPFC neurons with McN-A-343, an M1R-preferring agonist with high functional M1R selectivity that has been widely used to delineate M1R effects (Davies et al., 2001; Mitchelson, 2012) . McN-A-343 iontophoresis resulted in suppression of DLPFC neuronal trial activity (n = 18; p = 0.043, sign-rank test; Figure S2A ), whereby 61% of neurons (n = 11) were significantly suppressed. The proportion of suppressed neurons was similar between both M1R agonists. Next, we examined the physiological effects of M1R blockade with the selective antagonist, pirenzepine. M1R blockade also led to overall suppression of the neuronal population tested (n = 47; Figure 3A , top panel), just reaching significance (p = 0.047). Pirenzepine application significantly suppressed half of the tested DLPFC neurons (Figure 3A , bottom; n = 47, p < 0.05, rank-sum test on each neuron). Suppression of DLPFC activity by M1R blockade was only significant at higher dose ranges (21-100 nA; Figure 3B , right panel) and not for lower Pie chart (bottom) shows the proportion of PFC neurons that were significantly excited (pink) or inhibited (blue) by the drug or where the drug had no effect (yellow). Significance was determined on each neuron with the rank-sum test (p < 0.05). (B) Average PFC neuronal activity for neurons tested with M1R stimulation at low-dose range (0-20 nA; left) and high-dose range (21-100 nA; right). Control, black bars; low-dose M1R stimulation, gray; high-dose stimulation, light gray. Pie charts below show the proportion of neurons by effect for low (left) and high (right) dose ranges (same format as A). (C) Average population activity of PFC neurons is shown for control (black), M1R stimulation (gray), and recovery (brown) after drug application. Significance testing with sign-rank test and Holm-Bonferroni correction for multiple comparisons. Error bars: ± SEM. doses (0-20 nA; left panel). The proportion of significantly inhibited neurons was not different for pirenzepine application at low and high dose ranges ( Figure 3B , pie charts; p = 1; Fisher exact test, low versus high dose; low dose, 55%; high dose, 54% suppressed). Neurons tested for recovery from drug effects (n = 22) showed no significant restoration of activity after pirenzepine-induced suppression ( Figure 3C ). However, when we examined the final 200 s of the drug and recovery conditions, population average activity was significantly different (control versus final 200 s pirenzepine application, p = 0.002; final 200 s pirenzepine versus final 200 s recovery, p = 0.002; signrank test), suggesting that recovery was prolonged. Thus, M1R blockade also suppressed DLPFC activity, and while neuronal suppression was stronger at higher doses, there was a ceiling on the proportion of inhibited neurons due to M1R blockade.
We also classified recorded PFC neurons on the basis of waveform width into narrow-spiking (NS) and broad-spiking (BS) waveforms ( Figures 4A and 4B ). M1R stimulation significantly inhibited most tested NS neurons ( Figure 4C ; 7/8 significantly inhibited) and 22/39 BS neurons (11/36 excited). M1R blockade significantly inhibited 8/12 NS neurons ( Figure 4D ; 3/12 excited) and 16/35 BS neurons (9/35 excited).
Next, we examined the effects of M1R modulation on DLPFC activity in specific task epochs (STAR Methods): 0.6 s after rule cue onset (early-rule epoch), 0.6 s prior to stimulus onset (laterule), and a 0.6 s period encompassing stimulus onset, saccade, and reward (post-stimulus epoch). A two-way ANOVA of neuronal activity with factors drug condition and epoch for M1R stimulation resulted in significant effect of drug (F 1,276 = 9.92; p = 0.0018), but no significant effect of the trial epoch or the interaction (drug 3 epoch). M1R stimulation significantly decreased DLPFC activity in all epochs ( Figure S3A ; sign-rank test with Holm-Bonferroni correction). With M1R blockade at all doses, there were no significant effects of drug, epoch, or the interaction (drug 3 epoch). M1R blockade overall only significantly suppressed activity in the post-stimulus epoch ( Figure S3B ; sign-rank test with Holm-Bonferroni correction). However, at high doses of the M1R antagonist, the effect of the drug was significant (two-way ANOVA, F 1,228 = 8.05; p = 0.005), while the main effects of epoch and the interaction were not.
Effects of M1R Agents on Task Selectivity of DLPFC Neuronal Activity
We categorized DLPFC neurons using ANOVAs (STAR Methods) of trial activity for each neuron during the memory (delay) epoch to delineate neurons with rule-selective WM activity and during the stimulus and post-saccade epochs to identify neurons with saccade direction selectivity and stimulus location selectivity. The numbers of neurons in each defined population for both drugs tested are shown in Table 1 . Neuronal populations selective for task attributes were not defined to be mutually exclusive, and many neurons displayed multiple forms of task selectivity. We then examined drug effects on trial rule, saccade direction, and stimulus location selectivity in these respective populations by analyzing the area under the receiver operating characteristic curve (AUROC; Green and Swets, 1966) . Figures 5A and 5B show two example DLPFC neurons possessing rule selectivity in the memory epoch that were challenged with M1R stimulation. The neuron in Figure 5A exhibited greater control period activity prior to stimulus onset during prosaccades than antisaccade trials (top panel; Activity control = 5.94 Hz; AUROC control = 0.74). M1R stimulation significantly suppressed neuronal activity (bottom panel; Activity drug = 4 Hz, p < 0.0001) and deteriorated the difference in prestimulus activity between prosaccade and antisaccade trials, thus reducing rule selectivity in WM (AUROC drug = 0.69). Another neuron ( Figure 5B ) had greater delay epoch activity for antisaccade rule trials immediately prior to stimulus onset (top panel; Activity control = 2.16 Hz; AUROC = 0.64). This neuron was tested with successive doses of VU0357017 (20 and 40 nA, second and third panels, respectively). Increasing doses of M1R stimulation progressively decreased neuronal activity (Activity lowdose = 1.75 Hz, p control-low = 0.0001; Activity highdose = 0.18 Hz, p low-high < 0.0001). Subsequently, the neuron's activity was restored during the recovery condition (Activity recovery = 2.37 Hz; p control-recovery = 0.09). Concomitant with changes in neuronal excitability, trial rule selectivity diminished with increasing doses, especially for the high dose (AUROC control = 0.64; AUROC low = 0.62; AUROC high = 0.52) and was restored during recovery compared to the high dose agonist application (AUROC recovery = 0.59). In some neurons, M1R stimulation increased activity and increased rule selectivity. Figure S4A shows a DLPFC neuron with prestimulus preference for the antisaccade rule (top panel; Activity control = 5.37 Hz; AUROC control = 0.66). M1R stimulation increased neuronal activity (bottom; Activity drug = 8.68 Hz) and increased neuronal antisaccade selectivity (AUROC drug = 0.73). The M1R-preferring agonist McN-A-343 also suppressed DLPFC neuronal rule selectivity ( Figure S2B ). Pneumatic pressure ejection of the M1R agonist also reduced activity of a DLPFC rule-selective neuron ( Figure S4B ) and reduced trial rule selectivity, which recovered after cessation of the drug.
Trial Rule Selectivity
Next, we examined the effects of M1R blockade on DLPFC neuronal rule selectivity. Figure 5C shows a DLPFC neuron with prestimulus preference for prosaccade trials (top panel; Activity control = 10.46 Hz; AUROC control = 0.82). Pirenzepine application suppressed the activity of this neuron (bottom panel; Activity drug = 4.80Hz; p control-drug < 0.0001) and diminished rule selectivity (AUROC drug = 0.70). To ascertain the overall effects of M1R stimulation and blockade on trial rule selectivity in our population of neurons, we analyzed all rule-selective neurons tested with either drug. M1R stimulation marginally reduced population rule selectivity (n = 18 rule-selective neurons), but this effect did not reach significance (AUROC control = 0.61 ± 0.01; AUROC drug = 0.59 ± 0.02; p = 0.17, signrank test). It is possible that M1R stimulation initially augments rule selectivity, but this degrades as drug application proceeds. However, we found that rule AUROCs in the 200 s immediately after drug application initiation did not significantly change (n = 18; p = 0.2; sign-rank test). We then analyzed population effects of VU0357017 separately at low (0-20 nA) and high (21-100 nA) doses. Population-normalized spike density functions ( Figure 6A , top panel) for 13 neurons tested with low doses of VU0357017 show that the drug weakly suppressed population activity and had negligible effect on rule selectivity. This is further quantified by population AUROC values for rule activity for each neuron. (Figure 6B ; control, abscissa; low-dose drug application, ordinate). Although individual neuronal AUROCs increased or decreased upon drug application, there was no significant shift in overall population AUROCs above or below the equality line, indicating that low-dose drug application did not have systematic effects on rule selectivity (AUROC control = 0.59 ± 0.01; AUROC drug = 0.59 ± 0.02; p = 0.95). Population-normalized spike density functions for 12 neurons tested with high doses of VU0357017 ( Figure 6C ) demonstrate drug-induced collapse of population activity for preferred and nonpreferred rules and accompanying reduction in rule selectivity. Population AUROCs plotted for control and highdose drug application ( Figure 6D ) showed a shift of neuronal AUROCs below the equality line, indicating significant disruption of rule selectivity (AUROC control = 0.62 ± 0.01; AUROC drug = 0.55 ± 0.02; p = 0.021). Moreover, change in rule selectivity was not significantly correlated with activity suppression due to the M1R agonist at all doses (n = 18, Pearson's correlation coefficient, R = 0.4, p = 0.06) and at low doses (n = 13, R = 0.48, p = 0.09). However, for higher dose application of the M1R agonist, changes in the AUROC were significantly correlated with activity changes (n = 12, R = 0.58, p = 0.048), indicating that neuronal activity suppression led to reduction in population rule selectivity.
It is conceivable that, in the population response, strong excitation of neurons that showed increases in rule selectivity could offset the reduction in selectivity observed in the majority of neurons after suppression due to M1R agonist. To preclude this possibility, we constructed bootstrapped pro-and antisaccade (STAR Methods) trials by averaging randomly sampled trials from the 12 neurons tested with high doses of M1R agonist. AUROC analysis on this bootstrapped dataset also demonstrated reduction in population rule selectivity ( Figure S5 ). Thus, M1R overstimulation at high doses was detrimental to selectivity for trial rules because of general suppression of activity in DLPFC neurons.
An analysis of the effects of M1R blockade with pirenzepine on population rule selectivity in 26 rule-selective neurons revealed no significant changes due to M1R blockade (AUROC control = 0.617 ± 0.01; AUROC drug = 0.595 ± 0.01; p = 0.12, sign-rank test). We then analyzed population selectivity for low (0-20 nA) and high (21-100 nA) dose ranges of pirenzepine application. Population-normalized spike density functions for 13 neurons tested at low doses ( Figure 7A ) and for 21 neurons at high doses ( Figure 7C ) show that pirenzepine application did not appreciably change activity differences between preferred and nonpreferred rule trials. AUROCs demonstrated no significant overall effect of M1R blockade at both dose ranges on population rule selectivity (low doses, Figure 7B , p = 0.147; high doses, Figure 7D , p = 0.455). Thus, M1R blockade, while influencing trial rule-related activity of individual PFC neurons, did not have a significant overall effect on rule selectivity of the neuronal population.
Saccade Direction Selectivity
We performed a similar analysis of M1R modulation for DLPFC neurons displaying selectivity for the direction of the saccade executed (contralateral or ipsilateral to the recording hemisphere). Figure S6A shows activity of a DLPFC neuron preferring contralateral saccades. During the control period, this neuron was activated at saccade onset and had differential postsaccadic activity for contra-and ipsilateral saccades (top panel; saccade direction AUROC control = 0.79). M1R blockade suppressed neuronal activity and reduced postsaccadic directional selectivity therein (AUROC drug = 0.63). Figure S6B shows the activity of another DLPFC neuron with preference for the contralateral saccade that was tested with successive doses of pirenzepine, (top panel; AUROC control = 0.59). Low-dose (15 nA) pirenzepine application did not affect overall neuronal activity (p control-low = 0.09). However, the activity decrease was more pronounced for ipsilateral saccades (D contralateral = 1.23 Hz; D ipsilateral = 2.3 Hz; p < 0.0001), thereby increasing postsaccade direction selectivity (AUROC low-dose = 0.65). Subsequent higher dose M1R blockade suppressed overall activity (p control-high < 0.0001) and decreased postsaccade direction selectivity (AUROC high = 0.56). Saccade-direction AUROCs were significantly reduced by M1R blockade in the saccade-selective neuronal population (n = 31; p = 0.007; AUROC control = 0.65 ± 0.01; AUROC drug = 0.61 ± 0.01). In 20 neurons selective for contralateral saccades, pirenzepine reduced overall population AUROCs ( Figure S6C ; p = 0.0001, sign-rank test). This selectivity disruption was due to a greater decrease in activity for contralateral than ipsilateral saccades ( Figure S6D ; p = 0.001). In 11 ipsilateral saccade-selective neurons, pirenzepine had no effect on saccade selectivity (p = 0.91). In contrast, M1R stimulation with VU0357017 had no significant effect on population saccade selectivity of contralateral saccade-selective neurons (n = 18; p = 0.472, sign-rank test on AUROC, drug versus control). Thus, moderate levels of M1R stimulation appear to be necessary for the maintenance of saccade-related activity in PFC neurons, while overstimulation beyond endogenous cholinergic stimulation does not disrupt this activity.
We also analyzed the effects of M1R stimulation and blockade on neurons possessing selectivity for the peripheral stimulus direction. We found that neither M1R stimulation (n = 11, p = 0.10; sign-rank test) nor blockade (n = 16, p = 0.35) affected population stimulus direction selectivity measured by AUROCs.
In summary, the major consequence of local stimulation of M1Rs was suppression of DLPFC neuronal activity, with disruption of trial rule selectivity at higher doses. M1R blockade also suppressed DLPFC activity overall, albeit to a lesser extent, and had no systematic effects on trial rule selectivity, but affected the selectivity of postsaccadic activity.
DISCUSSION
We found that local stimulation of M1Rs suppressed PFC neuronal activity in macaques and overstimulation at higher doses was detrimental to trial rule representation. Increasing doses of M1R stimulation progressively increased the proportion of inhibited PFC neurons, while individual exemplars of increased excitability proportionally decreased. M1R blockade also marginally suppressed PFC activity, but the proportion of PFC neurons suppressed or excited by M1R antagonism did not show dose dependence. Moreover, M1R blockade spared rule WM and stimulus direction representations in PFC, but disrupted selectivity in neuronal postsaccadic activity for contralateral saccades. Since we have previously shown that general muscarinic blockade diminishes all aspects of task selectivity in PFC (Major et al., 2015) , our results here showing only modest effects of M1R blockade on task selectivity suggest that another muscarinic receptor subtype, such as the M2R, may be responsible for disruptive effects of general muscarinic blockade on WM activity. These findings proffer a cautionary note to strategies for pharmacological treatment of cognitive dysfunction based on M1R stimulation (Conn et al., 2009 ).
M1R Modulation of Neuronal Excitability in DLPFC
Several studies imputing an excitatory role for M1Rs in modulating cortical activity informed our prior hypotheses that M1R stimulation would increase PFC activity, and conversely, that M1R blockade would reduce PFC excitability, thus resembling the effects of general muscarinic blockade in PFC (Major et al., 2015; Zhou et al., 2011) . Muscarinic stimulation of neurons in rodent cortical slices induces transient inhibition followed by prolonged excitation of cortical neurons (Gulledge et al., 2009; McCormick and Prince, 1985) . Pirenzepine counteracts the slow excitation, but not the inhibitory component (McCormick and Prince, 1985) , and blocks ACh-induced excitation of rat parietal cortical neurons (Bradshaw et al., 1987) . Pirenzepine also blocks persistent discharges induced by stimulation in the presence of cholinergic agonist carbachol in rodent entorhinal cortical slices, indicating that M1R is the conduit of this effect (Egorov et al., 2002) . Muscarinic stimulation induces a slow afterdepolarization in rodent medial PFC that is mediated by nonselective cationic conductances Andrade, 1996, 1998) and inhibits KCNQ channels that carry the M-current (Brown and Adams, 1980) . Moreover, blockade of the M-current reduces spatial WM activity in macaque PFC (Wang et al., 2011) . Thus, there are many identified mechanisms by which muscarinic stimulation would be expected to increase cortical excitability. However, M1R mechanisms have also been implicated in the transient inhibitory responses of cortical neurons to ACh application. Hyperpolarizing responses to ACh application have been attributed to GABAergic mechanisms, through direct excitation of inhibitory interneurons Prince, 1985, 1986) . Other studies reveal that brief muscarinic stimulation results in IP3 receptor-mediated Ca 2+ release, which subsequently activates SK potassium channels, resulting in neuronal inhibition (Gulledge and Stuart, 2005) . We found that, in awake, taskengaged monkeys, 81% of PFC neurons at higher doses of M1R stimulation were inhibited (62% at all doses), while the proportion of excited neurons dose-dependently reduced. This argues that, in primates with engaged arousal systems and normal cholinergic tone, M1R stimulation predominantly engages the inhibitory mechanisms summarized above. We also found that M1R blockade suppressed overall PFC activity. However, the proportions of pirenzepine-inhibited neurons remained approximately half of the neurons tested regardless of the dose. Inhibition due to both blockade and stimulation of M1R suggests that, in awake, behaving primates, there are some M1R-mediated excitatory mechanisms, including activation of nonselective cation channels and inhibition of the M-current, that may, however, be near-maximally engaged by endogenous tonic ACh levels. At higher levels of cholinergic stimulation of M1Rs, as engendered by agonist application, cortical excitability is reduced, either through mechanisms dependent on GABAergic feedforward inhibition (McCormick and Prince, 1985) , or by activation of SK potassium channels through IP3/Ca 2+ . Here, analysis of excitability of neurons classified by waveform shape suggested that M1R stimulation did not lead to increased excitability of parvalbumin-positive (PV+) interneurons, which typically possess NS waveform properties (Kawaguchi and Kubota, 1993) . On the contrary, our data suggest that NS interneurons were more strongly inhibited by M1R stimulation than BS neurons (88% inhibited versus 59% for BS neurons). Thus, feedforward inhibition due to increased excitability of PV+ interneurons may not explain the inhibitory effects of M1R stimulation here. However, we cannot rule out cholinergic mechanisms involving other interneuron types possessing BS-like waveforms in explaining our results (Kawaguchi and Kubota, 1993) . Moreover, atypical excitatory neurons, like the thin-spiking pyramidal tract neurons found in macaque motor areas (Vigneswaran et al., 2011) , may confound interpretation of these results. Yi et al. (2014) found that muscarinic agonist muscarine potentiated current-induced activity in PV+ interneurons in both hippocampus and PFC slices in mice. Knocking out M1Rs in PV+ interneurons eliminated this effect in hippocampal interneurons. However, the authors did not investigate the consequences of M1R genetic deletion on muscarinic activation of PV+ interneurons in PFC, so it is unclear if M1Rs were also responsible for muscarine's actions on PFC PV+ interneurons. We propose that our findings with M1R stimulation are instead explained by G q -transduced activation of the IP3 receptor pathway leading to an increase in SK channel conductance as described above. Notably, G q -coupled a1-adrenergic receptor stimulation reduces the excitability of macaque DLPFC WM neurons through actions on protein kinase C (Birnbaum et al., 2004) , while focal activation of G q -coupled metabotropic glutamate receptor type I triggers dendrosomatic Ca 2+ waves in rat PFC neurons, which induce transient inhibition/prolonged excitation similar to muscarinic activation (Hagenston et al., 2008) . Consistently, blockade of IP3 receptors or SK channel blockade in rat medial PFC improves WM performance (Brennan et al., 2008) . One confound of this proposed mechanism is that inhibitory SK channel inhibitory responses in rodent cortical slices decline over time, due to Ca 2+ depletion after repeated cholinergic stimulation at resting membrane potentials. However, this decline does not occur at membrane potentials closer to threshold, when Ca 2+ stores are rapidly replenished (Dasari et al., 2017) .
Since in awake, behaving primates, the cortical neuronal membrane potential is close to the spike threshold (Tan et al., 2014) , SK channel responses may remain potent with prolonged M1R stimulation, and continue unabated, unlike cortical slices. Another confound of this mechanistic hypothesis is that M1R-mediated inhibition in slices is transient and followed by prolonged increase in excitability. Gulledge et al. (2009) found that both inhibitory and excitatory responses to cholinergic stimulation with carbachol were diminished in PFC slices from M1R knockout mice. Our results suggest that tonic M1R stimulation with iontophoresis or pulsed stimulation with pressure ejection results in inhibition of a majority of PFC neurons in behaving monkeys. It is possible we did not observe the excitatory phase of tonic M1R-dependent cholinergic stimulation in our experiments because of species differences or differences between cholinergic responses in cortical slices and intact cortical circuitry in awake, behaving animals, where cholinergic stimulation may already be substantial due to endogenous cholinergic tone. Alternatively, excitatory actions of M1R may manifest only in some cortical layers and not others (Gulledge et al., 2009 ). Nevertheless, the PFC neuronal inhibition by M1R agonist application we observe with both methodologies (but not by saline) indicates that, in behaving primates, overstimulation of M1Rs directly suppresses PFC neuronal activity through proximal signal transduction mechanisms, and that normal cortical cholinergic tone reflects an optimal balance between inhibitory and excitatory muscarinic modulation of frontal cortex through M1Rs.
M1R Modulation of Behavioral Task Representation in PFC Activity
Trial activity of DLPFC neurons encodes selectivity for many task attributes in the pro-and antisaccade task, including maintenance of the task set in WM (rule representation), post-stimulus activity encoding stimulus location, and perisaccadic representation of the saccade direction (Everling and DeSouza, 2005) . Previously, we demonstrated that general muscarinic blockade with scopolamine suppressed PFC neuronal rule, stimulus location, and saccade direction selectivity (Major et al., 2015) . Systemic scopolamine injections also reduce PFC WM activity during memory-guided saccades, and disrupt behavioral performance (Zhou et al., 2011) . We hypothesized that the disruptive effects of muscarinic blockade on PFC task selectivity are mediated by M1Rs because they are the most abundant muscarinic subtype in cortex (Flynn et al., 1995) and they are localized at asymmetric synapses in spines and dendrites, poised to regulate glutamatergic transmission (Mrzljak et al., 1993) .
Here we found, using an identical experimental paradigm as Major et al. (2015) , that unlike general muscarinic blockade, M1R blockade had no consistent effects on population rule selectivity, even though rule representation in WM in individual PFC neurons was affected. Moreover, this was the case at both lower and higher doses, notwithstanding suppression of memory period activity at higher doses (Figure 3) . Thus, our results suggest that the previously reported strong suppression of rule selectivity in WM by scopolamine (Major et al., 2015) is not mediated by M1Rs. Consistent with this, intraventricular injections of pirenzepine in rats had subtler effects on delayed match to position performance compared to scopolamine (Andrews et al., 1994) . Intriguingly, mice lacking M1Rs have selective deficits only in certain kinds of delayed-response performance, which may need cortico-hippocampal connectivity (Anagnostaras et al., 2003) . We have recently reported that general cholinergic stimulation with iontophoresis of carbachol excited a greater proportion of DLPFC neurons (49%) than our results with M1R stimulation here, also reducing neuronal rule selectivity (Major et al., 2018) . Since ACh actions in cortex are thought to be primarily mediated by muscarinic receptors (Cox et al., 1994) , our previous results with carbachol considered with our results with M1R here suggest that other muscarinic receptor subtypes may have a more defining role in activity for rules and task set. M2Rs are also expressed in DLPFC and, in addition to presynaptic expression suggesting a role in modulating neurotransmitter release, are expressed in pyramidal neurons mostly in spines of apical dendrites apposed to glutamatergic synapses (Mrzljak et al., 1993 (Mrzljak et al., , 1998 . M2Rs are G i/o -coupled (Hulme et al., 1990) and their activation would be expected to decrease cAMP signaling. ACh application in mouse visual cortical slices at low and high doses enhanced and suppressed evoked neuronal responses, respectively, and the excitatory effect is blocked in M2R/M4R knockout mice (Kuczewski et al., 2005) . Previous iontophoretic studies have shown that increased cAMP signaling through dopamine D1 receptors (G s -coupled) suppresses macaque PFC neuronal activity (Vijayraghavan et al., 2007) , while decrease in cAMP signaling, e.g., through G i/o -coupled a2A receptor stimulation, increases DLPFC spatial WM activity (Wang et al., 2007) . Thus, postsynaptic M2R activation in pyramidal neurons would be expected to increase PFC persistent activity, and may be the main effector of muscarinic modulation of rule representations in PFC. Future experiments examining this hypothesis are of paramount interest.
M1R stimulation at lower doses also did not affect rule selectivity in WM, but M1R overstimulation at higher doses disrupted trial rule selectivity. This suggests that M1R may have an equivocal role in maintenance of rules in WM at low (as mimicked by M1R blockade) to moderate levels of engagement, while excessive M1R stimulation disrupts cognitive representations, due to substantial general suppression of cortical activity. The reason for this discrepancy may be the engagement of different downstream signaling mechanisms by these M1R agents. Future experiments manipulating the pharmacology of individual signaling components downstream of M1R may shed light on this. This is intriguing because systemic M1R stimulation can be beneficial in some cognitive tasks in monkeys (Shirey et al., 2009; Uslaner et al., 2013) . However, it is difficult to compare systemic injections with the local PFC manipulations here. Our finding that prolonged overstimulation of M1R degrades rule WM is interesting given a recent study that found intermittent stimulation of the cholinergic nucleus basalis was beneficial to WM performance, while continuous stimulation had adverse effects (Liu et al., 2017) .
We also found that M1R blockade, while sparing rule maintenance in WM, attenuated saccade direction selectivity of PFC neurons in the postsaccadic epoch, while M1R stimulation did not affect this activity. This may be another indicator that different signaling mechanisms downstream of M1R differentially modulate cognitive representations. Previously, dopamine D2 receptors were shown to modulate perisaccadic activity during memory-guided saccades (Wang et al., 2004) and in the antisaccade task (Vijayraghavan et al., 2016) , but did not have consistent effects on WM for spatial stimuli and rules, respectively. This resembles our findings here with M1R blockade. Location-selective perisaccadic activity in PFC has been hypothesized to carry feedback signals from the superior colliculus updating the frontal eye fields about an executed eye movement (Sommer and Wurtz, 2006) . However, its role in periprincipal PFC is not entirely clear (Vijayraghavan et al., 2017) . Interestingly, most macaque nucleus basalis cholinergic neurons are active during the response/reward epoch, and not the delay epoch of a delayed response task, with most activity predicting rewarding or aversive stimuli (Richardson and DeLong, 1986) . This suggests that phasic ACh release coincident with the motor response may strengthen information about rewarded actions after a trial. Our results suggest that endogenous M1R engagement may have a role in modulating this function.
M1R stimulation has been viewed with promise in the development of new cognitive enhancers (Melancon et al., 2013) . Conventional cholinergic enhancement using cholinesterase inhibitors has dubious efficacy in the treatment of dementia in Alzheimer's disease (Fisher, 2008) . Since this disease is characterized by degeneration of the cholinergic system, directly targeting downstream receptors may be more effective. Indeed, M1R allosteric modulators have shown some promise in enhancing cognitive performance in animal models (Shirey et al., 2009; Uslaner et al., 2013) , with fewer side effects than cholinesterase inhibitors (Vardigan et al., 2015) . However, our results with M1R modulation of DLPFC cognitive physiology suggest that, in primates, M1R overstimulation in the PFC may be detrimental to cognitive performance. These results will inform treatment strategies based on M1Rs for use in neuropsychiatric disorders. Our results also broach the hypothesis that excitatory mechanisms modulating cognitive representations in PFC are mediated by other muscarinic receptor subtypes that may be potential targets for the synthesis next-generation cognitive enhancers for use in health and disease.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
These experiments were performed with two adult male rhesus monkeys (Macaca mulatta, age 9-11 years, weight 9-12 kg). Subjects were individually or pair-housed in temperature and humidity controlled environments maintained in a 12-hour light cycle. All procedures were performed in accordance with the Canadian Council on Animal Care policy and a protocol approved by the Animal Care Committee of the University of Western Ontario. Both subjects have previously served as subjects in other publications (Major et al., 2015 (Major et al., , 2018 Skoblenick and Everling, 2012; Vijayraghavan et al., 2016) . All experimental procedures and data analysis were similar to Vijayraghavan et al. (2016) .
METHOD DETAILS

Surgical procedures
Surgical procedures for implantation of a head-post and plastic recording chamber were as described previously (Skoblenick and Everling, 2012) . The recording chamber was placed over the right DLPFC, as guided by MRI, in both subjects, under anesthesia and employing standard aseptic techniques ( Figure 1A ). Subjects were administered post-operative antibiotics and analgesics and monitored by the university veterinarian.
Behavioral paradigm
The behavioral task, monitoring and reward delivery were implemented with the stimulus presentation system CORTEX (National Institutes of Mental Health, Bethesda, MD). The subjects performed a variant of the pro-and antisaccade task (Everling and DeSouza, 2005; Hallett, 1978) , where the trial rule had to be retained in working memory (Koval et al., 2011) . The subjects fixated on a white fixation spot (0.5 ), appearing centrally on a CRT monitor ( Figure 1C ). After 300 ms, the fixation spot briefly changed to green or red (100 ms), indicating the rule that was to be eventually applied to generate the motor response: pro-or antisaccades. Rule cue colors indicating prosaccade and antisaccade trials were counterbalanced between monkeys. In some experiments, the red and green fixation spots were made isoluminant. In a few sessions, the rule was instead indicated by central isoluminant horizontal or vertical bars (1 width). We pooled the data from these experiments because several groups, including ours, have previously shown that rule-selective activity of PFC neurons is robust, and occurs regardless of the sensory attributes of the rule cue (Vijayraghavan et al., 2016; Wallis et al., 2001) . The fixation spot reverted to white after 100 ms and the subject had to maintain the trial rule in working memory. Central fixation was further maintained for 800-1300 ms (pseudorandomly generated duration for each trial). In some sessions, we maintained a constant delay of 1200 ms. Subsequently, the fixation spot extinguished and after 200 ms (gap period), when the screen was blank, a peripheral stimulus (0.5 white spot) was presented at 13 eccentricity at one of two pseudorandomly chosen locations on the horizontal meridian to the left or right of the fixation spot. The subject had 500 ms to execute a saccade, and then held REAGENT post-saccade fixation for 120 ms. The subjects made saccadic response based on the previously remembered task rule, which could be a prosaccade toward the stimulus or an antisaccade away from the stimulus toward the opponent location on the horizontal meridian. Correct responses were reinforced with a water reward (approximately 125 ms after the saccade). The intertrial interval was 2 s after reward onset. The gap period was introduced to increase task difficulty (Bell et al., 2000) . The rule presented on each trial and the stimulus location was pseudorandomly chosen, and thus the subjects could not predict which rule or stimulus location would be presented on a given trial.
Neuronal recordings with microiontophoresis and pneumatic injections
The M1R allosteric agonist, VU0357017 hydrochloride, M1R-preferring agonist McN-A-343, and the M1R antagonist, pirenzepine dihydrochloride (Tocris Bioscience, Sigma-Aldrich) were dissolved (10 mM) in pH 3.5 deionized water and stored at À20 C in 30 mL aliquots.
Multi-barrel tungsten-in-glass electrodes were custom-fabricated and the design was derived from previous studies (Vijayraghavan et al., 2016) . Tungsten wire (50 mm diameter; Midwest Tungsten Service), cut to a length of approximately 11.2 cm, was tapered to a fine point by etching the wire in a solution of sodium nitrite and potassium hydroxide as previously described (Vijayraghavan et al., 2016) . Seven-barreled, non-filamented borosilicate glass (Friedrich-Dimmock) was pulled with the 50 mm tapered tungsten wire in the central barrel using a micropipette puller (PMP107el, MicroData Instrument). Figure 1B illustrates the electrode design and the iontophoresis technique. The resultant glass-coated recording tip was approximately 15-30 mm in diameter. Typical impedance at 1 kHz was 0.5-1.0 MU. The remaining barrels were top-filled with the drug solutions (VU0357017, pirenzepine, McN-A-343) and saline. The solutions were pneumatically pushed to the tip using air pressure. Barrel impedances (measured for direct current) of the drugs used in this study typically ranged from 35-300 MU. Electrode impedances and tip integrity were also examined upon conclusion of the recording session. Tungsten wires were then inserted into the drug barrels and used to pass current through them employing a iontophoretic constant current generator (NeuroPhore BH-2, Harvard Apparatus). The electrode was mounted on a hydraulic micromanipulator (MO-95, Narishige Group, Tokyo, Japan) and inserted through a 23-gauge dura-penetrating stainless steel guide tube into the brain. The location in the recording chamber was determined using a custom recording grid (Neuronitek) modified from the Crist grid (Crist Instrument). Grid coordinates for recordings were cross-referenced with MRI images.
Neuronal signals were buffered using a unity-gain headstage and the Omniplex system (Plexon), amplified 1000X, band-pass filtered (300-6000 Hz, 4-pole Bessel filter) for spike activity isolation and digitized at 40 kHz. Spikes were detected online using amplitude thresholding, followed by offline classification with principal component analysis using Offline Sorter (Plexon).
A holding/retention current was applied to barrels (À8 nA) when drugs were not being ejected to prevent leakage. In most experiments, current balancing was not employed, as it has been previously shown that there are no effects of currents of this magnitude on neuronal physiology in monkeys with this electrode design (Vijayraghavan et al., 2007) . Further, several studies have shown that different drugs ejected with identical currents and polarities have dissociable functional effects on physiological activity, often selective to cell type (Vijayraghavan et al., 2007 (Vijayraghavan et al., , 2016 Wang et al., 2004) . Additionally, to ensure that our results were not artifacts due to current application, in some sessions, we successively ejected Na + (from saline) and the M1R agonist with identical currents and polarity and found that Na + ejection did not result in comparable physiological effects as ejections of pharmacological substances (see Results; also see similar results from Vijayraghavan et al., 2007) . Further, Disney et al. (2007) have demonstrated that the pH adjustment of the drug solutions to optimize drug ionization does not affect neuronal physiology.
In some experiments (n = 6), in order to further ensure that drug effects were not an artifact of the iontophoretic methodology used for drug delivery, we ejected drugs using pneumatic pressure pulses for brief periods of time (50-125 ms) using a precision solenoid (PPM2 module, Harvard Apparatus). Electrode fabrication and drug loading was identical to the iontophoretic experiments, except that drugs were dissolved in normal saline for these experiments. We sealed Tygon tubing to the top opening of each filled drug barrel (instead of a wire for ejecting current) using cyanoacrylate and epoxy resin, which was then connected to the output of the solenoid valve system through a fluid circuit that allowed us to eject specific drugs loaded in the electrode. We empirically determined the pulse schedule range at which we were able to eject drugs without causing displacement of the neuron or neuronal death, as assessed by lack of effect of saline ejections or by recovery after drug ejections. We activated the solenoid using gating pulses driven by an Arduino ATmega2560 board. Gating pulse durations varied, but typically we applied 25-60 psi pulses of 50-125 ms at 1-2 Hz. Although we have not precisely quantified the volumes ejected with each pulse in the experiments described here, we estimate the volume is in the order of 10-30 picoliters per pulse. Since, our objective with these experiments was to qualitatively establish the direction of drug effects on the physiology of PFC neurons without using current based ejection, we do not think that the caveat posed by the lack of precise volume information detracts from the objective of the experiments here. Further, we did not include these neurons in any of the subsequent population analyses presented in the study.
Experimental design
Our experimental design involved data collection during a control condition followed by iontophoretic application of an M1R agonist/ antagonist (or saline) by continuous ejection. Multiple doses of the drugs were tested, sometimes successively in the same session, and in some sessions, a recovery condition was obtained after termination of drug application. At least 8 correct trials were obtained per rule and per stimulus direction combination, typically more. Recordings with less than 8 correct trials in each rule and stimulus direction combination in each condition were excluded from further analysis. Iontophoresis results in the ejection of very small amounts of charged drugs in the neuronal milieu, and is thus not expected to have behavioral consequences in areas with diffuse specialization such as the PFC (Major et al., 2015 (Major et al., , 2018 Vijayraghavan et al., 2016) . Thus, in this study we have restricted ourselves to presenting the physiological consequences of M1R neuromodulation, and not the effects on behavior.
QUANTIFICATION AND STATISTICAL ANALYSIS
After waveform sorting, all data was analyzed with custom-written scripts in MATLAB (MathWorks, Natick, MA).
Classification of waveform type
Cortical neurons can be classified into narrow-spiking (NS) and broad-spiking (BS) based on width of the spike waveform (Mountcastle et al., 1969) . NS neurons are generally thought to comprise of neocortical basket and chandelier cells expressing parvalbumin, and thus comprise a subset of cortical interneurons (Kawaguchi and Kubota, 1993) . However, the presence of thin-spiking regular spiking cells in cortex (Nowak et al., 2003) and of pyramidal tract neurons in macaque motor cortex with thin extracellular waveforms (Vigneswaran et al., 2011) may complicate this categorical correspondence. Nevertheless, identified pyramidal neurons in DLPFC have been shown mostly have broad spike waveforms and narrow-spiking neurons in macaque PFC were found to correspond to parvalbumin-expressing basket and chandelier cells (Krimer et al., 2005) . Further, Johnston et al. (2009) found that antidromically identified corticotectal neurons were broad-spiking. Since prior work that has found differences in neuromodulation of narrow and broad spiking neurons (Jacob et al., 2013) , we performed an analysis of spike waveform based categorization.
Waveforms were first spline interpolated to 1 ms resolution (Johnston et al., 2009) . We then normalized the average interpolated waveform from each recorded neuron, such that the normalized waveform ranged from À0.5 to 0.5. Waveforms were then aligned on the waveform trough (negative inflection) and the waveform peak (positive inflection) was marked for each neuron. We then computed the trough-peak time for each neuron, which has been correlated with the width of the intracellular action potential at half maximum (Krimer et al., 2005) . To examine the distribution of spike widths, and ensure that our distribution was robust to sample size, trough-peak time distribution for the population was pooled with a larger dataset that comprised of 179 recordings for which we have conducted spike width analysis in this and previous studies (Major et al., 2015) . We tested for unimodality of the trough-peak distribution using the Hartigan's dip test (Hartigan and Hartigan, 1985) . We found that trough-peak times were not distributed unimodally (n = 179; p = 0.03). Based on findings from previous studies, which examined antidromically identified macaque PFC projection neurons (Johnston et al., 2009) , and intracellular recordings from macaque PFC slices (Krimer et al., 2005) , we classified neurons as NS if the trough-peak duration was less than 250 ms. Our analysis yielded 20/94 NS neurons with median peak-trough duration of 195 ms (range: 133-244 ms), and BS neurons with median peak-trough duration of 465 ms (range: 276-626 ms).
Rasters and spike density functions
Spike density functions were constructed by convolving spike trains with a kernel reminiscent of the alpha function (Thompson et al., 1996; Vijayraghavan et al., 2016) :
where s is the convolved spike density function, t is time and the parameters a and t are the time constants for the growth and decline phases of the exponential function. We used a of 2 ms, and t of 100 ms to account for higher variability in PFC responses compared with sensory areas. Unlike the more commonly employed Gaussian convolution kernel, which results in a symmetric convolution around the spike and could thus erroneously attribute some of the impact of the spike prior to its occurrence, the spike impact using this kernel occurs completely after the occurrence of the spike (Thompson et al., 1996) .
Analysis of physiological effects
We excluded neurons with negligible activity (< 1 Hz throughout the control and relevant drug conditions) from further analysis. We calculated average activity (firing rate) across the entire trial (average trial denoted throughout the manuscript with the term Activity) from each neuron tested with a drug. We delineated the effects of the drug on individual neuronal activity by performing nonparametric Wilcoxson rank sum tests on the trial activity for each neuron between control and drug conditions. Neurons were deemed to have excited or inhibited on the basis of the test (p < 0.05). We counted the number of neurons that were excited, inhibited or unaffected using this analysis and constructed pie charts of the proportions of neurons. This analysis also extended to measuring the effects of individual dose-ranges of the drug. The Fisher exact test was used to assess if proportions of excited and inhibited neurons were significantly different from each other and to test if different doses of the drugs resulted in progressive inhibition or excitation of the population (see Results). We also calculated the population average activity for control and drug conditions for all doses, and low/high dose ranges. We examined whether there was significant effect of the drugs on average population activity using the paired Wilcoxon sign rank test (p < 0.05). We further examined physiological effects of the drugs in different epochs of the trial. For this analysis, we divided the trial into three epochs: early rule (0-600 ms after rule cue onset), late-rule (last 600 ms prior to peripheral stimulus onset) and post-stimulus epoch (0-500 ms after stimulus onset). We computed the average activity in these epochs as described above.
Classification of neurons based on task-selectivity
We classified task-selectivity of neurons in our population using ANOVAs as described previously (Vijayraghavan et al., 2016) . We performed the ANOVA analysis in task-relevant epochs defined as follows:
(1) Delay epoch: 600 ms before stimulus-onset to 70 ms after stimulus-onset (to account for the afferent delay in stimulus-related responses in DLPFC). We performed 2-way ANOVAs (factors: rule and drug) on trial activity in this epoch to delineate neurons with rule-selectivity. Previous studies (Major et al., 2015; Vijayraghavan et al., 2016) , have found that prominent rule-selectivity during proand antisaccades in PFC occurs at a latency of about 600ms prior to stimulus onset. Further, we were interested in rule selectivity in the time period directly preceding stimulus onset, when it could most directly have an impact on task performance. Based on the ANOVAs, we identified neurons as possessing rule-selectivity if there was a significant main effect of rule or a significant rule X drug interaction in this epoch. (2) Stimulus epoch: 70 ms after peripheral stimulus onset to 400 ms after stimulus onset. We performed 3-way ANOVAs (factors: rule, drug and stimulus location) on trial activity in this epoch from each neuron to identify stimulus locationselective neurons. Neurons were classified as selective for stimulus location if there was significant main effect of stimulus location or significant stimulus location X drug interaction in this epoch. (3) Postsaccadic epoch: 400 ms period after saccade onset. We performed 3-way ANOVAs (factors: rule, drug and saccade direction) on trial activity from each neuron in this epoch to identify postsaccade direction-selective neurons, which were defined by a significant main effect of saccade direction or significant saccade direction X drug interaction in this epoch. After data collection, saccade onsets were precisely marked using an eye-velocity threshold of 70 /s. Neurons classified by ANOVA were included in further analysis of drug effects on task selectivity. The proportions with which DLPFC neurons displayed individual activity types in the overall population are shown in Table 1 .
We then quantified rule, saccade direction and stimulus location selectivity in these individual populations defined by the ANOVA using signal detection theory and computing the area under the Receiver-Operating characteristic curves (AUROC) from spike counts (Green and Swets, 1966) in the relevant epoch, as described before (Vijayraghavan et al., 2016) . The AUROC metric has been extensively employed in analyzing categorical selectivity. The AUROC ranged from 0 to 1 with 0.5 indicating no selectivity, and values toward 0 or 1 indicating increasing selectivity for one of the opponent discriminants (i.e., prosaccade or antisaccade rule; contralateral or ipsilateral saccade; contralateral or ipsilateral stimulus location). By convention, we computed AUROC values such that AUROC > 0.5 indicated a preference for prosaccades, contralateral saccade direction and contralateral stimulus location, while AUROC < 0.5 indicated a preference for antisaccades, ipsilateral saccades and ipsilateral stimulus location. Neuronal selectivity (preferred rule, saccade direction or stimulus location versus nonpreferred) was determined based AUROC values in both control and drug conditions, to include neurons in which selectivity arose as a consequence of drug application (Vijayraghavan et al., 2007; Williams and Goldman-Rakic, 1995) . AUROC values were then reported based on preferred versus nonpreferred task rule, saccade direction or stimulus location. For example, for a neuron deemed to be antisaccade rule preferring, where the AUROC would be less than 0.5, we report the AUROC value for the neuron as [1-AUROC] for control and drug conditions. Population analysis of drug-induced changes in selectivity were performed by comparing pairwise neuronal AUROCs in the control and drug conditions using the sign rank test. The AUROC metric reflects only differences between activity for opponent task attributes. However, it is not sensitive to the raw neuronal activity that contributes to the selectivity. It is conceivable that increase/decrease in task selectivity in a minority of neurons accompanied by strong changes in neuronal activity can offset more numerous opponent changes in selectivity in a majority of the neurons with weaker opponent changes in activity. To address this possibility, we also performed another population analysis, wherein we randomly sampled the activity from 1 trial from each neuron in the population for a given task attribute and given condition (control or drug), and created bootstrapped trials with average activity from these randomly sampled trials across neurons. Thus, this averaged ''trial'' activity represented activity from all neurons. We repeated this to create a dataset of averaged activity bootstrapped trials for each task attribute (i.e., preferred rule trials or nonpreferred rule trials). To ensure that we maintained comparable sample sizes with the experiments, we adjusted the repetition so that the number of trials generated would be equal to the median trial counts in the neuronal dataset condition. From these trial sets we computed AUROCs. We ran the simulation for 1000 such datasets. AUROCs from this dataset would reflect many possible combinations of trial activity of these neurons, as if they were recorded simultaneously. If the changes in activity in individual neurons was much stronger than weaker changes in other neurons in the opponent direction, this analysis would provide an estimate of population selectivity changes that reflected such an effect.
After determining the preferred and nonpreferred trial type for each type of task selectivity (rule, saccade direction, stimulus location), we constructed min-max normalized spike density functions from each neuron to generate population normalized spike density functions as described previously (Vijayraghavan et al., 2016) .
